Placebo (for atorvastatin)

DRUG2 trials

Sponsors

Sanofi, Monash University

Conditions

Disability Free SurvivalElderlyHealthyHypercholesterolemiaIndependent Living

Phase 2

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

CompletedNCT01288469

SanofiHypercholesterolemia

Start: 2011-01-31End: 2011-09-30Updated: 2015-09-24

Phase 4

A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)

Active, not recruitingNCT02099123

Monash UniversityDisability Free Survival, Elderly, Healthy +1

Start: 2015-07-31End: 2025-12-31Updated: 2024-11-21

Related Papers

Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People

Journal of the American Heart Association2024-11-169 citations

STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals

BMJ Neurology Open2023-10-017 citations

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)

BMJ Open2023-04-0156 citations

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

Journal of the American College of Cardiology2017-01-30193 citations

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo.

2016-02-1336 citations

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the <scp>ODYSSEY OPTIONS</scp> Studies

Clinical Cardiology2014-09-3045 citations

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

2014-06-18160 citations

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.

2014-06-0172 citations

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

2012-10-31338 citations